Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:HHH NASDAQ:KRYS NASDAQ:PTCT NASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHHHHoward Hughes$79.69-1.5%$78.54$61.40▼$87.77$4.81B1.23380,774 shs260,349 shsKRYSKrystal Biotech$188.33-2.4%$159.67$122.80▼$207.84$5.59B0.64334,555 shs252,726 shsPTCTPTC Therapeutics$66.82-2.5%$56.98$35.51▼$69.48$5.44B0.551.19 million shs1.29 million shsTSHATaysha Gene Therapies$5.08-4.9%$3.43$1.05▼$5.51$1.46B0.9911.73 million shs4.71 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHHHHoward Hughes-1.73%-2.23%-2.59%+16.03%+3.37%KRYSKrystal Biotech-2.41%-0.23%+21.99%+27.69%+5.93%PTCTPTC Therapeutics-2.47%+1.23%+11.95%+40.29%+82.07%TSHATaysha Gene Therapies-4.87%+1.60%+78.87%+97.67%+150.25%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHHHHoward Hughes$79.69-1.5%$78.54$61.40▼$87.77$4.81B1.23380,774 shs260,349 shsKRYSKrystal Biotech$188.33-2.4%$159.67$122.80▼$207.84$5.59B0.64334,555 shs252,726 shsPTCTPTC Therapeutics$66.82-2.5%$56.98$35.51▼$69.48$5.44B0.551.19 million shs1.29 million shsTSHATaysha Gene Therapies$5.08-4.9%$3.43$1.05▼$5.51$1.46B0.9911.73 million shs4.71 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHHHHoward Hughes-1.73%-2.23%-2.59%+16.03%+3.37%KRYSKrystal Biotech-2.41%-0.23%+21.99%+27.69%+5.93%PTCTPTC Therapeutics-2.47%+1.23%+11.95%+40.29%+82.07%TSHATaysha Gene Therapies-4.87%+1.60%+78.87%+97.67%+150.25%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHHHHoward Hughes 2.80Moderate Buy$83.334.57% UpsideKRYSKrystal Biotech 2.75Moderate Buy$209.0010.98% UpsidePTCTPTC Therapeutics 2.53Moderate Buy$69.003.26% UpsideTSHATaysha Gene Therapies 2.80Moderate Buy$9.0077.17% UpsideCurrent Analyst Ratings BreakdownLatest TSHA, HHH, PTCT, and KRYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025HHHHoward HughesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/8/2025KRYSKrystal BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025PTCTPTC TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/8/2025TSHATaysha Gene TherapiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/2/2025TSHATaysha Gene TherapiesRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $12.0010/2/2025TSHATaysha Gene TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $10.009/27/2025HHHHoward HughesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/27/2025KRYSKrystal BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025PTCTPTC TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/27/2025TSHATaysha Gene TherapiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/22/2025HHHHoward HughesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 10/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHHHHoward Hughes$1.75B2.70$9.54 per share8.35$56.65 per share1.41KRYSKrystal Biotech$290.52M18.76$4.52 per share41.62$32.90 per share5.72PTCTPTC Therapeutics$806.78M6.58N/AN/A($14.24) per share-4.69TSHATaysha Gene Therapies$8.33M166.37N/AN/A$0.35 per share14.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHHHHoward Hughes$200.55M$4.5717.4486.62N/A12.85%10.51%3.15%N/AKRYSKrystal Biotech$89.16M$4.9238.2818.68N/A40.85%15.21%13.81%11/3/2025 (Estimated)PTCTPTC Therapeutics-$363.30M$6.979.59N/AN/A35.65%-106.31%30.61%11/6/2025 (Estimated)TSHATaysha Gene Therapies-$89.30M-$0.34N/AN/AN/A-1,144.97%-78.44%-44.82%11/12/2025 (Estimated)Latest TSHA, HHH, PTCT, and KRYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025TSHATaysha Gene Therapies-$0.09N/AN/AN/A$1.51 millionN/A11/6/2025Q3 2025PTCTPTC Therapeutics-$1.11N/AN/AN/A$177.42 millionN/A11/3/2025Q3 2025KRYSKrystal Biotech$1.04N/AN/AN/A$93.72 millionN/A8/12/2025Q2 2025TSHATaysha Gene Therapies-$0.07-$0.09-$0.02-$0.09$1.61 million$1.99 million8/7/2025Q2 2025PTCTPTC Therapeutics-$1.07-$0.83+$0.24-$0.83$173.01 million$178.88 million8/4/2025Q2 2025KRYSKrystal Biotech$1.08$1.29+$0.21$1.29$95.42 million$96.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHHHHoward HughesN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHHHHoward Hughes1.851.181.18KRYSKrystal BiotechN/A9.689.33PTCTPTC TherapeuticsN/A3.623.57TSHATaysha Gene Therapies0.1712.4812.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHHHHoward Hughes93.83%KRYSKrystal Biotech86.29%PTCTPTC TherapeuticsN/ATSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipHHHHoward Hughes48.00%KRYSKrystal Biotech13.70%PTCTPTC Therapeutics5.50%TSHATaysha Gene Therapies3.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHHHHoward Hughes60859.40 million30.89 millionOptionableKRYSKrystal Biotech21028.94 million24.98 millionOptionablePTCTPTC Therapeutics1,41079.44 million75.07 millionOptionableTSHATaysha Gene Therapies180272.80 million262.48 millionOptionableTSHA, HHH, PTCT, and KRYS HeadlinesRecent News About These CompaniesTaysha Gene Therapies Regains Full Rights to Rett Syndrome Program5 hours ago | marketwatch.comTaysha Gene Therapies regains full rights to TSHA-102 program5 hours ago | msn.comTaysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett SyndromeOctober 16 at 4:01 PM | globenewswire.comTaysha Gene Therapies (NASDAQ:TSHA) Hits New 52-Week High - Should You Buy?October 15 at 11:16 AM | marketbeat.comTruist Financial Remains a Buy on Taysha Gene Therapies (TSHA)October 12, 2025 | theglobeandmail.comTaysha Gene Therapies price target raised to $9 from $8 at BofAOctober 10, 2025 | msn.comWeiss Ratings Reiterates Sell (D-) Rating for Taysha Gene Therapies (NASDAQ:TSHA)October 9, 2025 | marketbeat.comTaysha Gene Therapies presents new supplemental data analysis from REVEAL studyOctober 9, 2025 | msn.comTaysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual MeetingOctober 9, 2025 | globenewswire.comTaysha Gene Therapies (NASDAQ:TSHA) Trading Down 4.9% - Time to Sell?October 6, 2025 | marketbeat.comTaysha Gene Therapies: Breakthrough Rett Program With BLA Acceleration PotentialOctober 6, 2025 | seekingalpha.comContrasting Taysha Gene Therapies (NASDAQ:TSHA) and Globeimmune (OTCMKTS:GBIM)October 6, 2025 | americanbankingnews.comTaysha Gene Therapies (TSHA) Gets a Buy from Canaccord GenuityOctober 5, 2025 | theglobeandmail.comTaysha Gene Therapies (TSHA) Receives a Buy from Truist FinancialOctober 5, 2025 | theglobeandmail.comHow Recent Developments Are Rewriting the Story for Taysha Gene TherapiesOctober 4, 2025 | finance.yahoo.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)October 3, 2025 | globenewswire.comTaysha Gene Therapies (NASDAQ:TSHA) Sees Unusually-High Trading Volume After Analyst UpgradeOctober 3, 2025 | marketbeat.comTaysha Gene Therapies stock soars after FDA breakthrough therapy designationOctober 2, 2025 | investing.comTaysha Gets Breakthrough-Therapy Designation for Investigational TreatmentOctober 2, 2025 | marketwatch.comDemystifying Taysha Gene Therapies: Insights From 6 Analyst ReviewsOctober 2, 2025 | benzinga.comTaysha soars on FDA breakthrough therapy status for lead assetOctober 2, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTSHA, HHH, PTCT, and KRYS Company DescriptionsHoward Hughes NYSE:HHH$79.69 -1.22 (-1.51%) Closing price 10/16/2025 03:59 PM EasternExtended Trading$79.92 +0.23 (+0.29%) As of 04:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Howard Hughes Holdings Inc., together with its subsidiaries, operates as a real estate development company in the United States. It operates in four segments: Operating Assets; Master Planned Communities (MPCs); Seaport; and Strategic Developments. The Operating Assets segment consists of developed or acquired retail, office, and multi-family properties along with other retail investments. Its MPCs segment develops, sells, and leases residential and commercial land designated for long-term community development projects in and around Las Vegas, Nevada; Houston, Texas; and Phoenix, Arizona. The Seaport segment is involved in the landlord operations, managed businesses, and events and sponsorships services of its restaurant, retail, and entertain properties in Pier 17, New York City; Historic Area/Uplands; and Tin Building, as well as in 250 Water Street and in the Jean-Georges restaurants. The Strategic Development segment develops and redevelops residential condominiums and commercial properties. It serves homebuilders. Howard Hughes Holdings Inc. was founded in 2010 and is headquartered in The Woodlands, Texas.Krystal Biotech NASDAQ:KRYS$188.33 -4.66 (-2.41%) Closing price 10/16/2025 04:00 PM EasternExtended Trading$188.30 -0.03 (-0.01%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.PTC Therapeutics NASDAQ:PTCT$66.82 -1.69 (-2.47%) Closing price 10/16/2025 04:00 PM EasternExtended Trading$66.30 -0.52 (-0.78%) As of 04:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Taysha Gene Therapies NASDAQ:TSHA$5.08 -0.26 (-4.87%) Closing price 10/16/2025 04:00 PM EasternExtended Trading$4.96 -0.12 (-2.26%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Buys Rival's Patent Treasure Trove in Strategic Move Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift Why Analysts Are Upgrading Ratings After Klarna's IPO Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
